Vesalic

Executive Summary

Vesalic is a UK-based biotechnology company that leverages artificial intelligence and machine learning to accelerate oncology drug discovery. By integrating computational biology with experimental validation, the company aims to identify novel drug targets and candidate molecules for more effective and personalized cancer treatments. Founded in 2012 and currently in the preclinical stage, Vesalic operates with a lean team of 1-50 employees. Although specific financial details are undisclosed, the company's AI-driven approach positions it within a rapidly growing sector of computational drug discovery. Vesalic's strategy to combine in silico prediction with wet-lab validation could potentially shorten development timelines and improve success rates in oncology.

Upcoming Catalysts (preview)

• Q1 2027Series A Financing60% success
• Q3 2026Lead Candidate Selection for Preclinical Development50% success
• Q2 2027Research Collaboration or Licensing Deal40% success